Clinical management of medulloblastoma in adults

Expert Review of Anticancer Therapy

Volumn 4, Issue 5, 2004, Pages 795-802

  Eisenstat, David D ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Adults; Brain tumor; Chemotherapy; Clinical trials; Medulloblastoma; Prognostic factors; Radiation therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; PREDNISONE; THIOTEPA; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADULT DISEASE; BONE MARROW TOXICITY; CANCER GROWTH; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL STUDY; CLINICAL TRIAL; HEARING LOSS; HUMAN; MEDULLOBLASTOMA; NEUTROPENIA; PERIPHERAL NEUROPATHY; REVIEW; THROMBOCYTOPENIA;

EID: 5444273591     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.5.795     Document Type: Review

References (43)

1. Giordana MT, Schiffer P, Lanotte M et al. Epidemiology of adult medulloblastoma. Int. J. Cancer 80, 689-692 (1999).
2. Roberts RO, Lynch CF, Jones MP, Hart MN. Medulloblastoma: a population-based study of 532 cases. J. Neuropathol. Exp. Neurol. 50, 134-144 (1991).
3. Brandes AA, Ermani M, Amista P et al. The treatment of adults with medulloblastoma: a prospective study. Int. J. Radiat. Oncol. Biol. Phys. 57, 755-761 (2003).
4. Boissel N, Auclerc MF, Lhéritier V et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J. Clin. Oncol. 21, 774-780 (2003).
5. Schiffer CA. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? J. Clin. Oncol. 21, 760-761 (2003).
6. Albright AL, Sposto R, Holmes E et al. Correlation of neurosurgical subspecialization with outcomes in children with malignant brain rumors. Neurosurgery 47, 879-885 (2000).
7. Zeltzer PM, Boyett JM, Finlay JL et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized Phase III study. J. Clin. Oncol. 17, 832-845 (1999 ).
8. Kortmann RD, Kühl J, Timmermann B et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int. J. Radiat. Oncol. Biol. Phys. 46, 269-279 (2000).
9. Taylor RE, Bailey CC, Robinson K et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 study. J. Clin. Oncol. 21, 1581-1591 (2003).
10. Thomas PRM, Deutsch M, Kepner JL et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J. Clin. Oncol. 18, 3004-3011 (2000).
11. Packer RJ, Goldwein J, Nicholson HS et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group study. J. Clin. Oncol. 17, 2127-2136 (1999).
12. Packer R, Gajjar A, Vezina G et al. Preliminary report of A9961: a Phase III randomized study of craniospinal radiotherapy (CSRT) followed by one of two adjuvant chemotherapy regimens (CCNU, CPDD, VCR or CPM, CPDD, VCR) in children with newly diagnosed average-risk medulloblastoma (MB). Proc. Int. Symp. Pediatr. Neurooncol. (2004) (Abstract Ther. 61).
13. Ellison DW, Clifford SC, Gajjar A, Gilbertson RJ. What's new in neurooncology? Recent advances in medulloblastoma. Eur. J. Pediatr. Neurol. 7, 53-66 (2003).
14. Fisher PG, Burger PC, Eberhart CG. Biologic risk stratification of medulloblastoma: the real time is now. J. Clin. Oncol. 22, 971-974 (2004).
15. Gilbertson RJ. Medulloblastoma: signalling a change in treatment. Lancet Oncol. 5, 209-218 (2004).
16. Wolden SL, Dunkel IJ, Souweidane MM et al. Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma. J. Clin. Oncol. 21, 3079-3083 (2003).
17. Carrie C, Lasset C, Alapetite C et al. Multivariate analysis of prognostic factors in adult patients with medulloblastoma. Retrospective study of 156 patients. Cancer 74, 2352-2360 (1994).
18. Frost PJ, Laperriere NJ, Wong CS et al. Medulloblastoma in adults. Int. J. Radiat. Oncol. Biol. Phys. 32, 951-957 (1995).
19. Prados MD, Warnick RE, Wara WM et al. Medulloblastoma in adults. Int. J. Radiat. Oncol. Biol. Phys. 32, 1145-1152 (1995 ).
20. Chan AW, Tarbell NJ, Black PM et al. Adult medulloblastoma: prognostic factors and patterns of relapse. Neurosurgery 47, 623-632 (2000).
21. Chang CH, Housepian EM, Hebert C Jr. An operative staging system and a megavoltage radiotherapeutic technique for cerebellar medulloblastomas. Radiology 93, 1351-1359 (1969).
22. Greenberg HS, Chamberlain MC, Glantz MJ, Wang S. Adult medulloblastoma: multiagent chemotherapy. Neurooncology 3, 29-34 (2001).
23. Kunschner LJ, Kuttesch J, Hess K, Yung WKA. Survival and recurrence factors in adult medulloblastoma: the MD Anderson Cancer Center experience from 1978 to 1998. Neurooncology 3, 167-173 (2001).
24. Abacioglu U, Uzel O, Sengoz M et al. Medulloblastoma in adults: treatment results and prognostic factors. Int. J. Radiat. Oncol. Biol. Phys. 54, 855-860 (2002).
25. Malheiros SMF, Franco CMR, Stavale JN et al. Medulloblastoma in adults. J. Neurooncol. 60, 247-253 (2002).
26. Malheiros SMF, Carrete H Jr, Stavale JN et al. MRI of medulloblastoma in adults. Neuroradiology 45, 463-467 (2003).
27. Giordana MT, Cavalla P, Chic, A et al. Prognostic factors in adult medulloblastoma. A clinico-pathologic study. Tumori 81, 338-346 (1995).
28. Sarkar C, Pramanik P, Karak AK et al. Are childhood and adult medulloblastomas different? A comparative study of clinicopathological features, proliferation index and apoptotic index. J. Neurooncol. 59, 49-61 (2002).
29. Giordana MT, Duo D, Gasverde S et al. MDM2 overexpression is associated with short survival in adults with medulloblastoma. Neurooncology 4, 115-122 (2002).
30. Zia MI, Forsyth P, Chaudry A et al. Possible benefits of high-dose chemotherapy and autologous stem cell transplantation for adults with recurrent medulloblastoma. Bone Marrow Transplant. 30, 565-569 (2002).
31. Millot F, Delval O, Giraud C et al. High dose chemotherapy with hematopoietic stem cell transplantation in adults with bone marrow relapse of medulloblastoma: report of two cases. Bone Marrow Transplant. 24, 1347-1349 (1999).
32. Carrie C, Hoffstetter S, Gomez F et al. Impact of targeting deviations on outcome in medulloblastoma: study of the French Society of Pediatric Oncology (SFOP). Int. J. Radiat. Oncol. Biol. Phys. 45, 435-439 (1999).
33. Gajjar A, Fouladi M, Walter AW et al. Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors. J. Clin. Oncol. 17, 1825-1828 (1999).
34. Fouladi M, Gajjar A, Boyett JM et al. Comparison of CSF cytology and spinal magnetic resonance imaging in the detection of leptomeningeal disease in pediatric medulloblastoma or primitive neuroectodermal tumor. J. Clin. Oncol. 17, 3234-3237 (1999).
35. Eberhart CG, Cohen KJ, Tihan T et al. Medulloblastomas with systemic metastases: evaluation of tumor histopathology and clinical behavior in 23 patients. J. Pediatr. Hematol. Oncol. 25, 198-203 (2003).
36. Brown HG, Kepner JL, Perlman EJ et al. Large cell/anaplastic medulloblastomas: a Pediatric Oncology Group Study. J. Neuropathol. Exp. Neurol. 59, 857-65 (2000).
37. Eberhart CG, Kepner JL, Goldthwaite PT et al. Histopathologic grading of medulloblastoma: a Pediatric Oncology Group Study. Cancer 94, 552-560 (2002).
38. Freeman CR, Taylor RE, Kortman RD, Carrie C. Radiotherapy for medulloblastoma in children: a perspective on current international clinical research efforts. Med. Pediatr. Oncol. 39, 99-108 (2002).
39. Merchant TE, Kun LE, Krasin MJ et al. A multi-institution prospective trial of reduced dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Int. J. Radiat. Oncol. Biol. Phys. 57(Suppl.), S194-S195 (2003).
40. Carrie C, Muracciole X, Gomez F et al. Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy and on-line quality control in standard risk medulloblastoma without chemotherapy. Results of the French M-SFOP 98 protocol. Int. J. Radiat. Oncol. Biol. Phys. 57(Suppl.), S195 (2003).
41. Tabori U, Hukin J, Crooks B et al. Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management. A Canadian Paediatric Brain Tumor Consortium Study. Proc. Int. Symp. Pediatr. Neurooncol. (2004) (Abstract Ther. 77).
42. Fernandez-Teijeiro A, Betensky RA, Sturla LM et al. Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J. Clin. Oncol. 22, 1-5 (2004 ).
43. Gajjar A, Hernan F, Kocak M et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J. Clin. Oncol. 22, 984-993 (2004).